Chronic myeloid leukemia stem cells

Mohammad Houshmand, Giorgia Simonetti, Paola Circosta, Valentina Gaidano, Alessandro Cignetti, Giovanni Martinelli, Giuseppe Saglio, Robert Peter Gale

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC). In humans a CML LSC is operationally-defined by ≥1 in vitro or in vivo assays of human leukemia cells transferred to immune-deficient mice. Results of these assays are sometimes discordant. There is also the unproved assumption that biological features of a CML LSC are stable. These considerations make accurate and precise identification of a CML LSC difficult or impossible. In this review, we consider biological features of CML LSCs defined by these assays. We also consider whether CML LSCs are susceptible to targeting by tyrosine kinase inhibitors (TKIs) and other drugs, and whether elimination of CML LSCs is needed to achieve therapy-free remission or cure CML.

Original languageEnglish
Pages (from-to)1543-1556
Number of pages14
JournalLeukemia
Volume33
Issue number7
DOIs
Publication statusPublished - Jul 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chronic myeloid leukemia stem cells'. Together they form a unique fingerprint.

Cite this